Cargando…
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) relies on the graft-versus-leukemia (GVL)-effect. Relapse after allo-HCT occurs in a considerable proportion of patients, and has a dismal prognosis with very limited curative potentia...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392688/ https://www.ncbi.nlm.nih.gov/pubmed/35460465 http://dx.doi.org/10.1007/s12185-022-03352-6 |
_version_ | 1784771118849064960 |
---|---|
author | Biavasco, Francesca Zeiser, Robert |
author_facet | Biavasco, Francesca Zeiser, Robert |
author_sort | Biavasco, Francesca |
collection | PubMed |
description | The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) relies on the graft-versus-leukemia (GVL)-effect. Relapse after allo-HCT occurs in a considerable proportion of patients, and has a dismal prognosis with very limited curative potential, especially for patients with FLT-ITD-mutated AML. Since the first description of sorafenib for treatment of FLT3-ITD-mutated AML, several clinical trials have tried to determine the efficacy of FLT3 inhibitors for preventing and treating AML relapse after allo-HSCT, but many questions regarding differences among compounds and mechanisms of action remain unanswered. This review provides an overview on the established and evolving use of FLT3 inhibitors to prevent or treat relapse of AML in the context of allo-HCT, focusing on the recently discovered immunogenic potential of some FLT3 inhibitors and addressing the possible mechanisms of leukemia drug-escape. |
format | Online Article Text |
id | pubmed-9392688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-93926882022-08-22 FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation Biavasco, Francesca Zeiser, Robert Int J Hematol Progress in Hematology The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) relies on the graft-versus-leukemia (GVL)-effect. Relapse after allo-HCT occurs in a considerable proportion of patients, and has a dismal prognosis with very limited curative potential, especially for patients with FLT-ITD-mutated AML. Since the first description of sorafenib for treatment of FLT3-ITD-mutated AML, several clinical trials have tried to determine the efficacy of FLT3 inhibitors for preventing and treating AML relapse after allo-HSCT, but many questions regarding differences among compounds and mechanisms of action remain unanswered. This review provides an overview on the established and evolving use of FLT3 inhibitors to prevent or treat relapse of AML in the context of allo-HCT, focusing on the recently discovered immunogenic potential of some FLT3 inhibitors and addressing the possible mechanisms of leukemia drug-escape. Springer Nature Singapore 2022-04-23 2022 /pmc/articles/PMC9392688/ /pubmed/35460465 http://dx.doi.org/10.1007/s12185-022-03352-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Progress in Hematology Biavasco, Francesca Zeiser, Robert FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation |
title | FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation |
title_full | FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation |
title_fullStr | FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation |
title_full_unstemmed | FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation |
title_short | FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation |
title_sort | flt3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation |
topic | Progress in Hematology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392688/ https://www.ncbi.nlm.nih.gov/pubmed/35460465 http://dx.doi.org/10.1007/s12185-022-03352-6 |
work_keys_str_mv | AT biavascofrancesca flt3inhibitortherapyforpreventionandtreatmentofrelapseafterallogeneichematopoieticcelltransplantation AT zeiserrobert flt3inhibitortherapyforpreventionandtreatmentofrelapseafterallogeneichematopoieticcelltransplantation |